The complexity of HLA‐G expression in ccRCC together with the extent of inter‐ and intratumor heterogeneity raises key questions regarding how tumors can be optimally sampled and what are the best targets to improve the clinical outcome of patients with ccRCC. Here, HLA-G is linked to nonpapillary renal cell carcinoma.